Alejandro Interián, Fernando Ramasco, Angels Figuerola, Rosa Méndez
{"title":"虚弱是脓毒症患者死亡率的独立预测因子。","authors":"Alejandro Interián, Fernando Ramasco, Angels Figuerola, Rosa Méndez","doi":"10.3390/jpm15090398","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objectives</b>: Personalized sepsis care requires understanding how pre-existing health status can influence outcomes. The aim of this study is to evaluate its impact on in-hospital and 12-month mortality in patients with sepsis, taking into account age, comorbidities, the Charlson Comorbidity Index, frailty, anemia, and the Sequential Organ Failure Score Assessment (SOFA) in the first 24 h. <b>Methods</b>: An observational and retrospective study was conducted using data from the Sepsis Code program at the Hospital Universitario de La Princesa. The relationship between risk factors and mortality, as well as Intensive Care Unit (ICU) admission, was analyzed for the period 2016-2018 using bivariate and multivariate logistic regression. <b>Results</b>: A total of 547 patients were included. In the multivariate analysis, the risk factors independently associated with mortality were Rockwood Clinical Frailty Scale ≥ 5 (OR 2.45, <i>p</i> < 0.05); SOFA ≥ 4 (OR 2.13, <i>p</i> < 0.05); age (OR 1.98, <i>p</i> < 0.05); anemia (OR 1.85, <i>p</i> < 0.05); and specific comorbidities such as ischemic heart disease (OR 2.34, <i>p</i> < 0.05), severe liver disease (OR 3.62, <i>p</i> < 0.05), and metastatic cancer (OR 3.14, <i>p</i> < 0.05). Patients who were frail, had dementia, or heart failure were less likely to be admitted to the ICU. <b>Conclusions</b>: Frailty, comorbidities, age, and anemia are associated with outcomes in patients with sepsis and could be incorporated into mortality prediction models to guide tailored treatment strategies.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470791/pdf/","citationCount":"0","resultStr":"{\"title\":\"Frailty as an Independent Predictor of Mortality in Patients with Sepsis.\",\"authors\":\"Alejandro Interián, Fernando Ramasco, Angels Figuerola, Rosa Méndez\",\"doi\":\"10.3390/jpm15090398\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objectives</b>: Personalized sepsis care requires understanding how pre-existing health status can influence outcomes. The aim of this study is to evaluate its impact on in-hospital and 12-month mortality in patients with sepsis, taking into account age, comorbidities, the Charlson Comorbidity Index, frailty, anemia, and the Sequential Organ Failure Score Assessment (SOFA) in the first 24 h. <b>Methods</b>: An observational and retrospective study was conducted using data from the Sepsis Code program at the Hospital Universitario de La Princesa. The relationship between risk factors and mortality, as well as Intensive Care Unit (ICU) admission, was analyzed for the period 2016-2018 using bivariate and multivariate logistic regression. <b>Results</b>: A total of 547 patients were included. In the multivariate analysis, the risk factors independently associated with mortality were Rockwood Clinical Frailty Scale ≥ 5 (OR 2.45, <i>p</i> < 0.05); SOFA ≥ 4 (OR 2.13, <i>p</i> < 0.05); age (OR 1.98, <i>p</i> < 0.05); anemia (OR 1.85, <i>p</i> < 0.05); and specific comorbidities such as ischemic heart disease (OR 2.34, <i>p</i> < 0.05), severe liver disease (OR 3.62, <i>p</i> < 0.05), and metastatic cancer (OR 3.14, <i>p</i> < 0.05). Patients who were frail, had dementia, or heart failure were less likely to be admitted to the ICU. <b>Conclusions</b>: Frailty, comorbidities, age, and anemia are associated with outcomes in patients with sepsis and could be incorporated into mortality prediction models to guide tailored treatment strategies.</p>\",\"PeriodicalId\":16722,\"journal\":{\"name\":\"Journal of Personalized Medicine\",\"volume\":\"15 9\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470791/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Personalized Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jpm15090398\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15090398","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
摘要
目的:个性化脓毒症护理需要了解预先存在的健康状况如何影响结果。本研究的目的是评估其对脓毒症患者住院和12个月死亡率的影响,考虑年龄、合并症、Charlson合并症指数、虚弱、贫血和前24小时的序贯器官衰竭评分评估(SOFA)。方法:观察性和回顾性研究使用来自公主大学医院脓毒症代码项目的数据。采用双变量和多变量logistic回归分析2016-2018年期间危险因素与死亡率以及重症监护病房(ICU)入院的关系。结果:共纳入547例患者。在多因素分析中,与死亡率独立相关的危险因素为Rockwood临床虚弱量表≥5 (OR 2.45, p < 0.05);SOFA≥4 (OR 2.13, p < 0.05);年龄(OR 1.98, p < 0.05);贫血(OR 1.85, p < 0.05);特定的合并症,如缺血性心脏病(OR 2.34, p < 0.05)、严重肝病(OR 3.62, p < 0.05)和转移性癌症(OR 3.14, p < 0.05)。体弱、痴呆或心力衰竭的患者被ICU收治的可能性较小。结论:虚弱、合并症、年龄和贫血与败血症患者的预后相关,可纳入死亡率预测模型,以指导量身定制的治疗策略。
Frailty as an Independent Predictor of Mortality in Patients with Sepsis.
Objectives: Personalized sepsis care requires understanding how pre-existing health status can influence outcomes. The aim of this study is to evaluate its impact on in-hospital and 12-month mortality in patients with sepsis, taking into account age, comorbidities, the Charlson Comorbidity Index, frailty, anemia, and the Sequential Organ Failure Score Assessment (SOFA) in the first 24 h. Methods: An observational and retrospective study was conducted using data from the Sepsis Code program at the Hospital Universitario de La Princesa. The relationship between risk factors and mortality, as well as Intensive Care Unit (ICU) admission, was analyzed for the period 2016-2018 using bivariate and multivariate logistic regression. Results: A total of 547 patients were included. In the multivariate analysis, the risk factors independently associated with mortality were Rockwood Clinical Frailty Scale ≥ 5 (OR 2.45, p < 0.05); SOFA ≥ 4 (OR 2.13, p < 0.05); age (OR 1.98, p < 0.05); anemia (OR 1.85, p < 0.05); and specific comorbidities such as ischemic heart disease (OR 2.34, p < 0.05), severe liver disease (OR 3.62, p < 0.05), and metastatic cancer (OR 3.14, p < 0.05). Patients who were frail, had dementia, or heart failure were less likely to be admitted to the ICU. Conclusions: Frailty, comorbidities, age, and anemia are associated with outcomes in patients with sepsis and could be incorporated into mortality prediction models to guide tailored treatment strategies.
期刊介绍:
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.